Soleno Therapeutics Corp (SLNO): Price/Earnings to Growth Multiple

Symbol and logo of brand Soleno Therapeutics Corp (SLNO)

Soleno Therapeutics develops cutting-edge treatments for rare pathologies, planning to monetize a therapy for Prader-Willi syndrome. The firm's environmental policy is limited to standard laboratory waste control. The business relies on the unique, first-in-class drug Diazoxide Choline. Current P/E growth dynamics illustrate market expectations, while 0.04 captures the current state of the parameter.

SLNO soleno.life Price/Earnings to Growth Multiple (07/04/2022 - 05/30/2026)

Analytical breakdowns for Soleno Therapeutics, Inc. (SLNO)

Fundamental company analysis:SLNO - Soleno Therapeutics Corp
Signature product of soleno.life

To identify undervalued assets, investors utilize the PEG ratio, which relates the P/E ratio to earnings growth rates: a value below one signals potential for price appreciation. In the case of Soleno Therapeutics (SLNO), this calculation allows for an assessment of the company's market value considering its future monopoly in the treatment of Prader-Willi syndrome, making the historical PEG level a key indicator of investment efficiency.

Competitors of Soleno Therapeutics

ASND (Ascendis) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio madrigalpharma.com MDGL|CORT - Price/Earnings to Growth Multiple|Rhythm Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate Akero Therapeutics Inc|MTSR (Metsera) - Price/Earnings to Growth Multiple|MLTX: Company Value to Earnings Growth Ratio|CRNX (Crinetics Corp) - PEG Multiple|PEG Multiple NewAmsterdam Pharma|PEG Multiple FOLD|Price/Earnings to Growth Ratio ETNB (89bio Inc)|Price/Earnings to Growth Ratio agios.com AGIO|Structure Corp (GPCR) - Price to Earnings Adjusted for Growth Rate|MDXG - Price/Earnings to Growth Ratio|RZLT: Price/Earnings to Growth Ratio|LXRX: PEG Multiple|MBX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Altimmune Pharma|Aardvark Pharma (AARD) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio sagimet.com (SGMT)|Price/Earnings to Growth Multiple BioAge Labs, Inc. BIOA|PEG Multiple BMEA (Biomea Fusion)|Price to Net Income Growth Ratio quincetx.com|GUTS - Price/Earnings to Growth Ratio|vTv Therapeutics, Inc. - Company Value to Earnings Growth Ratio|ATPC: PEG Multiple|Pluri Inc (PLUR) - PEG Multiple|Price/Earnings to Growth Ratio Synlogic, Inc.|Price to Earnings Adjusted for Growth Rate Lipocine LPCN|Price/Earnings to Growth Ratio Matinas BioPharma Holdings Inc. (MTNB)|Price/Earnings to Growth Multiple Spruce Biosciences SPRB|Galecto Corp - Price/Earnings to Growth Multiple|carmellrx.com - Price/Earnings to Growth Ratio|LUMO - Price/Earnings to Growth Ratio|ONVO: Price/Earnings to Growth Ratio|Radius Health (RDUS) - Price/Earnings to Growth Ratio